B.C. funding decision on pricey drug leaves teen with rare disease facing 'scary' future

CBC News

13 January 2020 - Miles Ambridge just misses cut-off age to access Spinraza, a potentially life-changing treatment.

B.C. has expanded its coverage of an exorbitantly expensive drug that could make a huge difference for Miles Ambridge's future, but at 14 years old, he's just a bit too old to qualify.

Ambridge has a rare neuromuscular disease called spinal muscular atrophy, a progressive condition that is slowly robbing him of his strength and his ability to move and breathe.

Read CBC News article

Michael Wonder

Posted by:

Michael Wonder